263 related articles for article (PubMed ID: 25164260)
21. Anti-tumor necrosis factor agents and placental transfer: relevant clinical data for rational decision-making.
Kane S
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):293-4. PubMed ID: 23247325
[No Abstract] [Full Text] [Related]
22. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.
Cullen G; Kroshinsky D; Cheifetz AS; Korzenik JR
Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1318-27. PubMed ID: 21957906
[TBL] [Abstract][Full Text] [Related]
23. The use of biologic agents in pregnancy and breastfeeding.
Horst S; Kane S
Gastroenterol Clin North Am; 2014 Sep; 43(3):495-508. PubMed ID: 25110255
[TBL] [Abstract][Full Text] [Related]
24. Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants.
Kattah MG; Milush JM; Burt T; McCabe RP; Whang MI; Ma A; Mahadevan U
Clin Transl Gastroenterol; 2018 Apr; 9(4):143. PubMed ID: 29618720
[TBL] [Abstract][Full Text] [Related]
25. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis.
Mozaffari S; Abdolghaffari AH; Nikfar S; Abdollahi M
Hum Exp Toxicol; 2015 May; 34(5):445-59. PubMed ID: 25378092
[TBL] [Abstract][Full Text] [Related]
26. A Narrative Review on Anti-Tumor Necrosis Factor α Therapies in Inflammatory Bowel Disease During Pregnancy: Immunoglobulin Placental Translocation and its Impact.
Roseira J; Ramos J
Acta Med Port; 2019 Apr; 32(4):305-312. PubMed ID: 31067425
[TBL] [Abstract][Full Text] [Related]
27. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
[TBL] [Abstract][Full Text] [Related]
28. Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update.
Leso V; Leggio L; Armuzzi A; Gasbarrini G; Gasbarrini A; Addolorato G
Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):779-86. PubMed ID: 19786877
[TBL] [Abstract][Full Text] [Related]
29. Certolizumab for rheumatoid arthritis.
Markatseli TE; Papagoras C; Nikoli A; Voulgari PV; Drosos AA
Clin Exp Rheumatol; 2014; 32(3):415-23. PubMed ID: 24447441
[TBL] [Abstract][Full Text] [Related]
30. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.
Lemaitre M; Kirchgesner J; Rudnichi A; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
JAMA; 2017 Nov; 318(17):1679-1686. PubMed ID: 29114832
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.
Punzi L; Lapadula G; Mathieu A
BioDrugs; 2014 Apr; 28 Suppl 1():S25-37. PubMed ID: 24687236
[TBL] [Abstract][Full Text] [Related]
32. Ischaemic colitis in rheumatoid arthritis patients receiving tumour necrosis factor-α inhibitors: an analysis of reports to the US FDA Adverse Event Reporting System.
Salk A; Stobaugh DJ; Deepak P; Ehrenpreis ED
Drug Saf; 2013 May; 36(5):329-34. PubMed ID: 23580194
[TBL] [Abstract][Full Text] [Related]
33. Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab.
Verma HD; Scherl EJ; Jacob VE; Bosworth BP
J Dig Dis; 2011 Oct; 12(5):379-83. PubMed ID: 21955431
[TBL] [Abstract][Full Text] [Related]
34. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy.
Zelinkova Z; de Haar C; de Ridder L; Pierik MJ; Kuipers EJ; Peppelenbosch MP; van der Woude CJ
Aliment Pharmacol Ther; 2011 May; 33(9):1053-8. PubMed ID: 21366638
[TBL] [Abstract][Full Text] [Related]
35. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease.
Casanova MJ; Chaparro M; Domènech E; Barreiro-de Acosta M; Bermejo F; Iglesias E; Gomollón F; Rodrigo L; Calvet X; Esteve M; García-Planella E; García-López S; Taxonera C; Calvo M; López M; Ginard D; Gómez-García M; Garrido E; Pérez-Calle JL; Beltrán B; Piqueras M; Saro C; Botella B; Dueñas C; Ponferrada A; Mañosa M; García-Sánchez V; Maté J; Gisbert JP
Am J Gastroenterol; 2013 Mar; 108(3):433-40. PubMed ID: 23318480
[TBL] [Abstract][Full Text] [Related]
36. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
Smith LS; Nelson M; Dolder CR
Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
[TBL] [Abstract][Full Text] [Related]
37. Risk of extraintestinal solid cancer with anti-TNF therapy in adults with inflammatory bowel disease: review of the literature.
Hudesman D; Lichtiger S; Sands B
Inflamm Bowel Dis; 2013 Mar; 19(3):644-9. PubMed ID: 23314243
[TBL] [Abstract][Full Text] [Related]
38. Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System.
Stobaugh DJ; Deepak P; Ehrenpreis ED
J Am Acad Dermatol; 2013 Sep; 69(3):393-8. PubMed ID: 23683730
[TBL] [Abstract][Full Text] [Related]
39. Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease.
Seirafi M; de Vroey B; Amiot A; Seksik P; Roblin X; Allez M; Peyrin-Biroulet L; Marteau P; Cadiot G; Laharie D; Boureille A; De Vos M; Savoye G; Rahier JF; Carbonnel F; Bonaz B; Colombel JF; Bouhnik Y
Aliment Pharmacol Ther; 2014 Aug; 40(4):363-73. PubMed ID: 24980270
[TBL] [Abstract][Full Text] [Related]
40. Increased hospitalizations in elderly with inflammatory bowel disease on anti-tumor necrosis factor therapy but not increased infections: a community practice experience.
Shen H; Lipka S; Katz S
J Crohns Colitis; 2014 Aug; 8(8):898-9. PubMed ID: 24434182
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
